Seeking Alpha
  • Today - Thursday, October 2, 2014

  • 5:04 AM
    • Richard Branson's Virgin Money is planning its IPO in London this month, and expects to raise about £150M ($243M) from the offering.
    • The bank is expected to aim for a £2B valuation, and shares will be sold equivalent to about 25% of the bank's capital.
    • Virgin Money will also return £50M of the proceeds to the British government as part of its payment plan for the purchase of Northern Rock, a British bank that was nationalized during the financial crisis, completing its acquisition price of £1B.
    | Comment!
  • Wednesday, October 1, 2014

  • 4:38 PM
    • Enterprise cloud storage/file-syncing leader BOX's IPO "probably won’t happen until 2015 because of volatile market conditions," Bloomberg reports. Box filed a public S-1 back in March, and was once expected to go public by this summer (if not sooner).
    • Market volatility, of course, didn't stop Alibaba from recently doing a blockbuster IPO. Box has been looking to soothe investor concerns about the cash burn caused by its heavy sales/marketing spend (still larger than revenue as of the 3 months ending April 30).
    • Box raised $150M in July at a $2.4B valuation. The funds extended the company's IPO runway. Since then, Amazon has launched a competing service, and Microsoft has aggressively slashed prices for its offerings.
    | 1 Comment
  • 11:06 AM
    • Franklin, North Carolina's Entegra Financial (NASDAQ:ENFC) is the holding company for Macon Bank, and priced its 6.55M share offering at $10 each.
    • The stock's up to $13.14 in early trading following the offering.
    • Source: Press Release
    • S-1
    | Comment!
  • 10:09 AM
    • After pricing its 20.6M-share IPO at $16 (the low end of a $16-$18 range), Vivint Solar (NYSE:VSLR) opened at $17.01 and is now at $16.20, up 1.3%.
    • The U.S. residential solar installer/electricity seller is worth $1.71B. It had cumulatively installed 129.7MW of systems as of June 30, and $547.5M in estimated nominal contracted payments (up from $223.3M a year earlier).
    • Prospectus, IPO preview, analysis
    • Update (11:37 AM): Shares are now up 8.2%.
    | Comment!
  • 9:33 AM
     
    • Shares of Zalando are up 14% in their IPO debut in Germany.
    • The public launch of the online fashion retailer has been closely watched with the stock considered a pure-play Internet bet and with it following close on the heels of Alibaba's emergence in the U.S.
    • Most of Zalando's revenue is churned up in Europe.
    | Comment!
  • 7:25 AM
    | 1 Comment
  • Tuesday, September 30, 2014

  • 4:52 PM
    • Redwood City, CA-based Dermira (Pending:DERM) is set for its IPO of 5.35M shares at $14 - 16. As the name implies, the clinical stage biopharmaceutical firm focuses on the dermatology space. It has three late-stage product candidates:
    • Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor (TNF inhibitor) for the treatment of moderate-to-severe plaque psoriasis. Cimzia is owned and marketed by Belgian biopharma firm UCB for other inflammatory diseases. Dermira signed a collaboration deal with UCB to develop Cimzia for psoriasis. It intends to commence a Phase 3 trial in 1H 2015.
    • DRM04, a topical small molecule anticholinergic for the treatment of hyperhidrosis. It blocks the action of acetylcholine and therefore blocks the activation of the sweat glands. Data from a Phase 2b trial should be available in 1H 2015. If successful, a Phase 3 trial will commence in 2H 2015.
    • DRM01, a topical small molecule sebum inhibitor for the treatment of acne. A Phase 2b clinical program, which may include more than one trial, should commence in 1H 2015.
    • S-1
    • ETFs: IBB, BIB, BIS
    | Comment!
  • 1:34 PM
    • Flint, Michigan-based Diplomat Pharmacy (DPLO) is set for its IPO of 13.3M shares at $14 - 16.
    • The company is the U.S.'s largest independent specialty pharmacy, founded in 1975. It focuses on specialty drugs that are typically administered on a recurring basis to treat patients with complex chronic diseases that require specialized handling and administration as part of their distribution process. It provides customized solutions for patients with cancer, MS, HIV, hepatitis, and other diseases as well as specialty infusion therapies for conditions like chronic genetic disorders (primarily hemophilia and immune globulin treatment).
    • 2013 financials: Revenues: $1.6B (+44.3%); Gross Profit: $112.6M (+62.5%); Operating Income: $12.0M (+144.9%); EPS: $0.14; CF Ops: $6.2M (+24.4%).
    • 1H 2014 financials: Revenues: $1.1B (+49.2%); Gross Profit: $67.1M (+65.3%); Operating Income: $9.3M (+99.8%); EPS: $0.11; CF Ops: $20.8M (+999%).
    • S-1
    • ETFs: IBB, BIB, BIS
    | Comment!
  • 1:11 PM
    • South San Francisco-based Calithera Biosciences (Pending:CALA) is on deck for its IPO. It will offer 6M shares at $11 - 15.
    • The early clinical-state company develops small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product in tumor metabolism is CB-839, a glutaminase inhibitor currently in Phase 1. Its lead preclinical program in tumor immunology is focused on arginase inhibitors. Phase 1 activities are not expected to begin until 2016, however.
    • The company lost ($12.4M) in operations in 2013 and ($9.6M) in 1H 2014.
    • S-1
    • ETFs: IBB, BIB, BIS
    | Comment!
  • Monday, September 29, 2014

  • 11:05 AM
    • 2 1/2 months after doing a successful IPO for its TerraForm Power solar project YieldCo (owns assets in the U.S., U.K., Canada, and Chile), SunEdison (SUNE +4.4%) says it has confidentially filed an S-1 for "a yieldco vehicle focused on contracted clean power generation assets in attractive, high growth, emerging markets, primarily in Asia (excluding Japan) and Africa."
    • SunEdison hasn't yet disclosed the size of the YieldCo's portfolio, or how much it's looking to raise. Investors are signaling their approval of the move.
    | 1 Comment
  • 7:24 AM
    • Dave & Buster's (Pending:PLAY) says it will offer 5.88M shares in a range of $16 to $18 per share.
    • The company expects to use the IPO funds to help it pay down debt.
    • Shares of PLAY will trade on the Nasdaq.
    • SEC Form S-1
    | Comment!
  • Friday, September 26, 2014

  • 8:09 AM
     
    • OnDeck Capital is close to filing for an IPO, according to Financial Times.
    • The P2P lender will follow Lending Club with its bid to raise capital through equity markets.
    • OnDeck already has Google Ventures and Peter Thiel as backers.
    | Comment!
  • Thursday, September 25, 2014

  • 10:06 AM
    • After pricing its IPO at $16 (the top of a $14-$16 range), Travelport (NYSE:TVPT) opened at $17.69 and is now at $16.88, up 5.5%. The travel distribution/commerce service provider is worth $2.03B, or 0.98x 2013 sales.
    • Travelport had 1H14 revenue of $1.12B (+4% Y/Y), and a net loss of $25M. Long-term debt totaled $3.21B as of June 30.
    • Prospectus, IPO preview
    | Comment!
  • 8:06 AM
    • Travelport Worldwide (NYSE:TVPT) raises $480M in its IPO after pricing the deal at the high end of the expected $14-$16 range, giving the company an enterprise value of $4.3B.
    • Blackstone (NYSE:BX) got involved in Travelport in 2006, injecting $775M of equity in a leveraged buyout, later increasing its investment to more than $800. The P-E firm later recouped nearly all of that in a dividend recap ... and then the recession hit.
    • Most of Blackstone's holding in TVPT was wiped out in 2011 when junior creditors took control. Today it owns 9.5% of Travelport and isn't selling any shares in the offering. The proceeds from the IPO will be used to cut debt.
    | Comment!
  • 7:41 AM
     
    • Tory Burch hires Roger Farah as its co-CEO to work alongside designer Tort Burch, according to the Wall Street Journal.
    • Farah is a former executive at Ralph Lauren.
    • There has been ongoing speculation that Tory Burch has been prepping for an IPO, although the company denies it.
    | Comment!
  • Wednesday, September 24, 2014

  • 1:50 PM
    • Shares of Smart & Final (NYSE:SFS) rally 6.7% above their initial pricing of $12 per share in their IPO debut.
    • The grocery store chain raised close to $160M in the offering to value the company at just under $1B.
    • SEC Form S-1
    | 2 Comments
  • 11:06 AM
    • After pricing its 5.36M-share IPO at $16 (above a $13-$15 range), CyberArk (NASDAQ:CYBR) opened at $25.00 and is now at $23.36, up 46%. The Israeli cybersecurity software vendor is valued at $691M, or 10.4x 2013 sales.
    • CyberArk had 1H14 revenue of $38.7M (+33% Y/Y), and nearly breakeven earnings. The company claims over 1,500 clients, including over 35% of the Fortune 100.
    • Prospectus, IPO preview
    | 1 Comment
  • 10:16 AM
    | 3 Comments
  • 7:55 AM
     
    • Larry Flynt is making some noise about taking his media empire public.
    • The founder of Hustler says an IPO could happen within 12 to 18 months at a valuation of close to $500M.
    • Flynt has strayed far beyond his monthly print magazine which only accounts for a small percentage of revenue. Casinos, a TV network, adults websites, and a licensing business are all under his corporate umbrella.
    | Comment!
  • 6:59 AM
    • BDC manager Medley Management (NYSE:MDLY) prices its 6M share IPO at $18 each vs. the expected offering range of $20-$22. The expected annual dividend of $0.80 per share makes for a 4.4% annualized yield.
    • Press release
    • Related: IPO Preview: Medley Management
    | Comment!
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector